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Background: Angioedema (AE) is idiopathic in the majority of cases. We studied patients with AE for genetic
variants of proteins involved with bradykinin generation and biodisposition.
Methods: One hundred sixty one patients with AE were recruited at a university hospital clinic. Patients were
categorized according to the proposed pathogenesis of AE: low C1 inhibitor (C1-INH) and C4 levels, autoimmune
disease, cancer, angiotensin-converting enzyme (ACE) inhibitor-induced, nonsteroidal antiinflammatory drug
(NSAID)-induced, or idiopathic. In addition, each patient had a blood sample analyzed for a complement profile and
enzymes (C1-INH and C4). Fifty-two of the patients were tested for genetic variants in factor XII, plasminogen-activator
inhibitor-1 (PAI-1), ACE, and aminopeptidase P (APP).
Results: The cause of angioedema was identified in 59/161 (37%) of the cases: 3 (2%) patients had a low plasma
C1-INH and C4; 20 (12%) were ACE inhibitor-induced; 12 (7%) were associated with autoimmune disorders; 7 (4%)
were associated with malignancy; and 17 (11%) were associated with NSAIDs. In the remaining 102 (63%) patients
the cause of angioedema was idiopathic. Of 52 patients with genetic analysis, 13 (25%) had a genetic variant in
APP, 10 (19%) in ACE, 13 (25%) in PAI-1, and 0 in Factor XII.
Conclusions: In addition to related diseases and medications causing AE, certain genetic variants encoding
proteins involved in bradykinin generation and/or catabolism pathways may be involved in the pathogenesis
of AE.
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Factor XIIBackground
Angioedema (AE) is a self-limited swelling in the dermis,
subcutaneous tissue, mucosa, and submucosa that can last
for hours to days [1]. It is a potentially life-threatening dis-
ease in cases of laryngeal AE. The pathophysiology differs
from urticaria, which involves the epidermis and dermis.
Several variants of angioedema exist making diagnosis and
initiating appropriate treatment difficult.* Correspondence: levy1@ualberta.ca
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unless otherwise stated.AE can be broadly categorized as those presenting with
and without associated urticaria. AE with urticaria is occa-
sionally allergic and due to food, medication, latex, insect
venom, or radiocontrast media [2], but many cases are idio-
pathic [3]. AE without urticaria can be non-histamine me-
diated due to C1 inhibitor (C1-INH) deficiency (hereditary
or acquired), or related to angiotensin converting enzyme
(ACE) inhibitor use, autoimmune diseases, malignancies, or
nonsteroidal anti-inflammatory drug (NSAID) use, but in
many cases is idiopathic.
Hereditary angioedema (HAE) is caused by mutations
in Serping1, which encodes C1-INH, a serine protease in-
hibitor that regulates activation of the classical and lectin
(and possibly the alternative) complement pathways andis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[4]. Pattern of inheritance is autosomal dominant in the
vast majority of affected patients who generally have par-
tial C1-INH deficiency [5,6] and cannot efficiently control
the contact activation system. Type I HAE is due to low
circulating levels of functional C1-INH, whereas type II is
due to normal to high levels of non-functional C1-INH.
Recently, HAE with normal C1-INH (type III) has been
described as an estrogen-related hereditary form with
normal functional levels of C1-INH and affecting predom-
inantly women who sometimes have a gain of function
variant of the gene coding for coagulation factor XII [7].
An acquired form of C1-INH deficiency also leads to AE
and is seen in patients with autoimmune disease or certain
malignancies [8]. Diagnosis of acquired C1-INH deficiency
requires a negative family history and its onset is usually
after the 4th decade of life, in contrast to hereditary
C1-INH deficiency. It is associated occasionally with
antibodies that react in vitro to C1-INH. AE due to ACE
inhibitor or NSAID use may present without urticarial
involvement or in concurrence with chronic spontan-
eous urticaria, which is defined as urticaria occurring
for at least six weeks due to an endogenous cause and
not external physical stimuli [9]. In many patients, AE
occurs in the absence of any known cause [10].
Non-histaminergic angioedema is most likely caused
by the generation of bradykinin, a potent vasoactive pep-
tide [11,12]. Bradykinin is generated mainly through acti-
vation of the contact system (Figure 1). Upon activation,
factor XII cleaves prekallikrein into kallikrein, which in










Figure 1 The fibrinolytic and contact pathways demonstrating the ge
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which bradykinin can be generated is via the fibrinolysis
pathway, although at a lesser extent. Indeed, plasmin,
generated from plasminogen by the action of the plas-
minogen activators, tissue plasminogen activator and
urokinase-like plasminogen activator, can cleave high
molecular weight kininogen into bradykinin. Activity of
tissue plasminogen activator and urokinase-like plas-
minogen activator is inhibited by plasminogen-activator
inhibitor-1 (PAI-1) [13]. Bradykinin is short-lived and
rapidly transformed by carboxypeptidase N into a bio-
active intermediate des-Arginine-9 bradykinin and/or
bioinactive intermediates by ACE and aminopeptidases
P (APP) [14] and M.
We hypothesize that defects in factors involved in
bradykinin generation or its catabolism may be associated
with AE attacks. This has been demonstrated in patients
who present with AE with neither C1-INH deficiency nor
any other known cause [10]. Some patients exhibit gain-
of-function mutations in factor XII that are suggested to
lead to increased activity, therefore increasing bradykinin
generation upon contact system activation [15]. Also,
polymorphisms affecting genes encoding ACE and APP
have been associated with increased levels of bradykinin
and/or des-Arg-9 bradykinin presumably related to re-
duced biodegradation [16]. Occurrence of these polymor-
phisms in addition to mutations in factor XII has been
shown in patients with estrogen-related AE [17]. Polymor-
phisms in XPNPEP2, which encodes APP, have been asso-
ciated with ACE inhibitor-associated AE [18,19]. Further,
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by allowing increased generation of plasmin. The 5G
variant is associated with less inhibition of plasminogen
activators and, consequently, increased conversion of
plasminogen to plasmin [21] and potentially more gen-
eration of bradykinin.
We studied patients with AE by genetic analysis for vari-
ants in genes encoding proteins involved in bradykinin
generation (factor XII, PAI-1) and enzymes involved in
bradykinin catabolism (ACE, APP). A further objective was
to classify patients according to etiology: decreased levels
of C1-INH and C4, ACE inhibitor-induced, autoimmune
disease, malignancy, NSAID-induced, or idiopathic.Methods
One hundred sixty-one patients presenting with AE at a
university hospital clinic were recruited. Diagnosis of
AE was made by an expert physician (GLS) based on
clinical history and direct physical examination. All pa-
tients provided informed written consent and ethics
approval was received through a research ethics board
(Canadian SHIELD, Burlington, ON, Canada). We ob-
tained a detailed clinical history including the location
of AE (central, peripheral, laryngeal, and/or abdominal),
family history of AE and other autoimmune disorders,
malignancies, autoimmune diseases, use of ACE inhibi-
tor or NSAID, and associated urticaria. Routine skin
prick tests to common airborne and environmental al-
lergens were done (ALK-Abelló, Port Washington, NY).
Each patient had a blood sample analyzed for antigenic
and functional levels of C1-INH and antigenic levels of
C4. C1-INH levels were measured either by immunone-
phelometry (Beckman Coulter, Brea, CA) or radial im-
munodiffusion (The Binding Site, San Diego, CA) and
C4 levels were assessed using immunonephelometry
(Beckman Coulter). C1-INH function was measured
using a standard chromogenic assay (Berichrom C1-INH,
Siemens, Erlangen, Germany). Patients were then cate-
gorized according to the proposed pathogenesis of AE:
low C1-INH and C4 levels, ACE inhibitor-induced,
autoimmune disease, malignancy, NSAID-induced, or
idiopathic. Blood specimens suitable for DNA extrac-
tion were available from 52 of the 161 patients. They
were tested for specific genetic variants in genes encod-
ing proteins or enzymes involved in direct or indirect
regulation of bradykinin generation and catabolism,
specifically factor XII, PAI-1, ACE, and APP. DNA
samples were analysed by standard molecular tech-
niques looking for the following genetic variants: factor
XII (mutation c.1032C > A or c.1032C > G), PAI-1 (4G/
5G polymorphism), ACE (insertion/deletion I/D poly-
morphism, Single Nucleotide Polymorphism Database
(dbSNP): rs1799752), APP (deletion g.2953-3127del, singlenucleotide polymorphism (SNP) c.-2399C > A, dbSNP:
rs3788853).
Whole blood was collected in EDTA and stored at −80°C
until used. Genomic DNA was extracted with the Qiagen
DNA extraction kit (Qiagen, California, USA). Each sample
was tested for 6 target genetic variants in 4 different genes
(XPNPEP2, ACE, F12, Serpine 1).Polymorphism and deletion in Aminopeptidase P
For Aminopeptidase P (APP), the gene XPNPEP2 is located
in chromosome Xq26.1. A polymorphism (c.-2399C >A) is
in the promoter region, while a 175-bp deletion is in exon
2 (g.2953-3127del) [22].
The primers for c.-2399C > A were: forward APP-SNP-
2 F 5′-TCC CCG TTT AGT TTG TTT GC-3′, reverse
APP-SNP-1R 5′-GGG CTA ATG TTG GTG ATG CT-
3′. 100 ng genomic DNA was subjected to PCR with
200 μM of dNTP, 1.5 mM of MgCl2, 1 μM of primers,
1.25U of Taq DNA polymerase Gold (ABI, Burlington,
ON, Canada), 1X buffer in a final volume of 25 μl in
ABI 9700 thermal cycler. The DNA was denatured at
95°C for 8 min followed with 35 cycles of 94°C for 50 sec,
56°C for 50 sec, and 72°C for 1 min. The extension is at
72°C for 10 min. Amplicons of PCR were sequenced to
detect this polymorphism.
The primers for g.2953-3127del were: forward APPdel-
3 F1 (5′-TTT CTC CCG GCT TCT AGC TT-3′), and
reversed primer APPdel-3R0 (5′-CTC AGC CAA AGG
CCA GTT AG-3′). 150 ng genomic DNA is subject to
PCR with 400 μM of dNTP, 0.8 μM of primers, 1 M of
betaine and 1.6U of long bp Taq DNA polymerase ELT
(Roche, Indianapolis, IN, USA), 1X buffer #2 in a final
volume of 30 μl. The DNA was first denatured at 95°C
for 7 min, cooled on ice, then with brief centrifugation,
followed by 35 cycles of 94°C for 3 min, 94°C for 50 sec,
63°C for 50 sec, 72°C for 1 min, and extension at 72°C
for 10 min.ACE polymorphism
The ACE gene encodes the angiotensin-converting en-
zyme (ACE). An insertion/deletion (I/D) polymorphism
is located in intron 16 of the gene. This polymorphism
is characterized by the presence (called I allele) or ab-
sence (called D allele) of a 287 bp Alu repeat sequence.
In Caucasians, the I allele is associated with lower,
and the D allele with higher circulating ACE activity,
respectively. The heterozygotes for insertion/deletion
(I/D) present about one-half of the variance of the
activity [23].
Forward primer ACE-I/D-F was 5′-CTG GAG AGC
CAC TCC CAT CCT TTCT-3′, reverse primer ACE-I/D-
R is 5′- GAC GTG GCC ATC ACATTC GTC AGA -3′.
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of dNTP, 0.8 μM of primers ACE-I/D-F and ACE-I/D-R,
1 M of betaine and 1.6U of long bp Taq DNA polymerase
ELT, 1X buffer #2 (Roche, Indianapolis, IN, USA) in a
final volume of 30 μl. The DNA was denatured at 95°C
for 7 min, cooled on ice before brief centrifugation,
followed by 35 cycles of 94°C for 3 min, 94°C for 50 sec,
63°C for 50 sec, 72°C for 1 min, and extension at 72°C
for 10 min.
Factor XII mutation
The F12 gene encodes coagulation factor XII (Hageman
factor). Mutations c.1032C > A and c.1032C > G are lo-
cated in exon 9 of the F12 gene. Forward primer FXII-
ex9-F2 was 5′-CTG GGA GTA CTG CGA CCT G-3′,
reverse primer FXII-ex9-R1 was 5′- AAG GCT GTG
GAG GAG CAG -3′. One hundred fifty ng no of
genomic DNA DNA was subject to PCR with 200 μM of
dNTP, 1 μM of primers, 1.5 mM of MgCl2, 1.25 U of Taq
DNA polymerase (ABI), 1X buffer, in a final volume of
30 μl. The PCR reaction started with denaturation at 94°C
for 10 min, followed by 35 cycles at 94°C for 50 sec, 63°C
for 50 sec, 72°C for 1 min, then extension at 72°C for
10 min. Amplicons generated were then sequenced.
PAI-1 polymorphism
Plasminogen activator inhibitor-1 is encoded by the
Serpine 1 gene. The 4G/5G polymorphism is located in
the promoter region. The 4G/4G genotype leads to a
significantly higher PAI-1 plasma concentration than
the 4G/5G and 5G/5G genotypes.
Forward primer serpine 1-F2 was 5′-CAC AGA GAG
AGT CTG GCC ACG T-3′, reverse primer serpine 1-R4
was 5′-CCA ACA GAG GAC TCT TGG TCT-3′. One
hundred fifty ng of genomic DNA was subjected to PCR
with 200 μM of dNTP, 1 μM of primers, 1.5 mM ofTable 1 Demographics of patients with angioedema
Entire cohort Subgroup of
patients with
genetic testing
Number of patients 161 52
Mean age (years) 50.6 52.3
Gender Male 64 (39.8%) 22 (42.3%)
Female 97 (60.2%) 30 (57.7%)
Presumed etiology ↓ C1-INH, C4 3 (1.9%) 0 (0%)
ACE-inhibitor 20 (12.4%) 3 (5.8%)
Malignancy 7 (4.3%) 3 (5.8%)
Autoimmune 12 (7.5%) 5 (9.6%)
NSAID 17 (10.6%) 2 (3.8%)
Idiopathic 102 (63.4%) 39 (75%)
C1-INH, C1 inhibitor; ACE-inhibitor, Angiotensin converting enzyme-inhibitor;
NSAID, Nonsteroidal anti-inflammatory drug.MgCl2, 1.25 U of Taq DNA polymerase (ABI), 1X buffer,
in a final volume of 30 μl. The PCR reaction is initiated by
denaturation at 94°C for 10 min, followed by 30 cycles at
94°C for 1 min, 63°C for 1 min, 72°C for 2 min, and exten-
sion at 72°C for 10 min. The PCR amplicons were digested
by restriction enzyme Bs1I for 3 hours followed by separ-
ation in a 3% agarose gel [24].Results
One hundred sixty-one patients between the ages of 14
and 86 presented with AE (Table 1). Sixty-four patients
were male and 97 were female with a mean age of 51 years.
Eighty-one percent of patients were of European descent,
15 percent were South Asian, and 4 percent were African
Caribbean. The cause of AE was identified in 59 (37%)
cases: 3 (2%) patients had a low plasma C1-INH and C4
levels; 20 (12%) were ACE inhibitor-induced;12 (7%) were
associated with autoimmune disorders; 7 (4%) were associ-
ated with malignancy; and 17 (11%) were related to use of
NSAIDs. In the remaining 102 (63%) patients, the cause
of AE was idiopathic. Atopy was not identified as a trigger
of angioedema in any of the patients. From the entire
cohort 67 (42%) patients experienced associated urticaria
with their AE which may be typical chronic spontaneous
urticaria, while the remaining 94 (58%) did not. In all pa-
tients the urticaria was a remote event and not considered
related to the angioedema with which they presented.
Fifty-two patients out of 161 had genotyping performed.
In this group, there were 22 males and 30 females ranging
from 24 to 88 years old, with a mean age of 53 years. As
seen in Table 2, 13 of the 52 (25%) patients had an identi-
fiable cause: 3 were associated ACE inhibitor use, 3 with
malignancy, 5 with autoimmune disease, 2 with NSAID
use, and no patients with low C1-INH and C4 levels. In
these patients with a known etiology there were a total of
7 mutations/polymorphisms in 6 individuals: 2 in APP
(SNP -2399C >A, dbSNP: rs3788853), 1 in ACE (inser-
tion/deletion I/D polymorphism, dbSNP: rs1799752), 2 in
PAI-1 (5G/5G polymorphism), and 1 in both ACE and
PAI-1.The deletions g.2953-3127 in APP and c.1032C >A
or c.1032C >G in factor XII were not detected in any pa-
tient. Those with idiopathic AE comprised the remaining
39 (75%) patients. Of these patients, 11 had a genetic vari-
ant in APP (SNP -2399C > A, dbSNP: rs3788853), 8 in
ACE, 10 in PAI-1, and none in APP (deletion g.2953-
3127del) or factor XII. These 29 genetic variants were
present in 22 of the idiopathic patients, as 7 of the patients
had variants in 2 different genes. Thus 22 of the 39 pa-
tients with idiopathic AE had a mutation or polymorph-
ism in one of the studied genes. Of all 52 patients tested,
13 (25%) patients had a specific genetic variant in APP
(SNP -2399C >A, dbSNP: rs3788853), 10 (19%) in ACE,
13 (25%) in PAI-1, and none in APP (deletion g.2953-
Table 2 Patients with a specific genetic variant categorized by presumed etiology






(deletion) (C/A) (A) (I/I polymorphism) (5G/5G polymorphism) (C/A, A, C/G, or G)
ACE-inhibitor (3) 0 0 0 0 1 (1.9%) 0 1 (1.9%)
Malignancy (3) 0 1 (1.9%) 0 0 0 0 1 (1.9%)
Autoimmune (5) 0 0 0 2 (3.8%) 2 (3.8%) 0 3 (5.8%)
NSAID (2) 0 0 1 (1.9%) 0 0 0 1 (1.9%)
Idiopathic (39) 0 7 (13.5%) 4 (7.7%) 8 (15.4%) 10 (19.2%) 0 22 (42.3%)
Total (52) 0 8 (15.4%) 5 (9.6%) 10 (19.2%) 13 (25%) 0 28 (53.8%)
APP, Aminopeptidase P; ACE, Angiotensin-converting enzyme; PAI-1, Plasminogen-activator inhibitor-1; NSAID, Nonsteroidal anti-inflammatory drug; SNP, Single
nucleotide polymorphism. Specific genetic variants were tested in the following genes: APP(deletion g.2953-3127del); APP, (SNP -2399C > A, dbSNP: rs3788853);
ACE(insertion/deletion I/D polymorphism, dbSNP: rs1799752)); PAI-1(4G/5G polymorphism); Factor XII( mutations c.1032C > A or c.1032C > G).*Some patients had a
genetic variant in multiple genes. Note: only significant genetic variants are reported, as indicated in title row.
Abbreviations: AE angioedema, C1-INH, C1-inhibitor, ACE angiotensin converting enzyme, NSAID nonsteroidal anti-inflammatory drug, HAE hereditary
angioedema, PAI-1 plasminogen-activator inhibitor-1, APP aminopeptidase P.
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ants in multiple genes were present in 9 patients.
Discussion
Several classifications of AE have been suggested over the
last few decades [10,17,25-27]. These include C1-INH de-
ficiency, use of medications such as ACE inhibitors or
NSAIDs, as well as autoimmune conditions and malignan-
cies. Recently, a new classification of AE has been proposed
by an international group of experts [10]. It is based on the
pattern of presentation (familial or sporadic) and level of
C1-INH (normal or low). In some cases, the underlying
cause can be identified. Once the offending medication has
been discontinued or the underlying disease has been
treated, the AE typically resolves, thus confirming the
causative factor. However, in many cases no underlying
cause is found and the AE is labeled as idiopathic. This of
course makes treatment decisions more difficult as there is
no specific treatment available. In our cohort, 63% of pa-
tients had idiopathic AE; however, while the proportion of
patients with idiopathic AE is not clearly reported in the
literature a relatively high rate is suspected by many cen-
ters [10]. The underlying etiology should help guide treat-
ment decisions. Therefore, discovering the etiology in
those with idiopathic AE could lead to better targeted
therapeutic options in these patients. We tested 52 pa-
tients with AE for genetic variants in genes encoding 4
proteins involved in the regulation of bradykinin gener-
ation or catabolism. Fifty-six percent of patients with
idiopathic AE had at least one genetic variant. Given
these findings we believe that a genetic predisposition
could be considered in some patients with AE: the pres-
ence of mutations or polymorphisms in factors involved
in generation and/or biodisposition of kinins.
Our cohort of 161 patients revealed that most present
with AE not related with C1-INH deficiency. Indeed, only
three patients demonstrated acquired angioedema withdiminished levels of C1-INH. In all three cases the AE
was linked to lymphoma and they each had a negative
family history for angioedema. The vast majority of pa-
tients are thus without effective specific etiology-based
treatment for either prophylaxis or acute episodes. The
presence of the genetic abnormalities we tested for could
help explain the occurrence of AE in many patients and
help better establish treatment options that could supple-
ment standard treatment. For example, a specific inhibitor
of kallikrein (Ecallantide) and/or a bradykinin B2 receptor
antagonist (Icatibant) could be used in patients with AE
not caused by C1-INH deficiency. Some reports show that
use of C1-INH concentrates or Icatibant in patients with
AE not linked to C1-INH deficiency have mixed results.
Response to treatment may depend on the underlying mu-
tation/polymorphism [10]. In those with genetic variants
of PAI-1, reduced or dysfunctional protein could lead to
more active fibrinolysis and presumably increased gener-
ation of bradykinin. Antifibrinolytic agents, such as
tranexamic acid and ε-aminocaproic acid, could be con-
sidered as a treatment of choice in these patients. In the
case of HAE or acquired AE, these medications could
supplement C1-INH concentrates as the clinical presen-
tation, severity, and frequency of AE attacks vary in pa-
tients with C1-INH deficiency, which may be explained
by genetic variants present in those patients. Angioedema
occurs in association with various clinical settings but the
risk and severity of attacks could be linked to the presence
of an allelic variant in one of the molecules involved in
bradykinin generation and/or catabolism. As new genetic
variants are discovered, more therapies can be developed
to target the implicated proteins.
It is possible that the genetic variants that we identi-
fied may actually be risk factors to developing AE. For
instance, the presence of the 5G/5G polymorphism asso-
ciated with a low level of PAI-1 leading to higher level
of generation of plasmin may predispose someone to
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inhibitors which decrease the biodisposition of kinins.
Similar rationale can be applied to those with AE
secondary to malignancy, autoimmune disease, or NSAID
use. Polymorphisms in APP and ACE lead to decreased
bradykinin biodegradation, whereas gain-of-function
mutations in factor XII increase its production.
One limitation of our study is that a control group
was not tested. Evaluation of the frequency of gene vari-
ant occurrence in a control population would be helpful
in assessing a potential role in development of AE. How-
ever, allele frequencies are highly influenced by ethnicity,
as reported for some variants we tested for such as PAI-1
[20,28] and ACE [29]. Only specific polymorphisms/muta-
tions in APP, ACE, PAI-1, and factor XII were tested. It is
likely that other regions of these genes or other genes in-
volved in the kinin-generating pathway may have variants
affecting protein function that can lead to altered regula-
tion of bradykinin. Based on European populations, for the
SNP –2399C >A (rs3788853), the frequency of allele C is
73%, while the frequency of allele A is 26% [30]. For the
4G/5G PAI-1 gene polymorphism, the frequency of 4G is
50% and the frequency of 5G is 50% [20,28]. For the I/D
polymorphism (rs1799752) in the ACE gene, the frequency
of D is 50% in Northern Europeans and 52% in Southern
Europeans, respectively, while the frequency of I is 50% in
Northern Europeans and 48% in Southern Europeans,
respectively [29]. In our patients presenting with angio-
edema these genetic variants, by themselves or in associ-
ation with other unknown cofactors, such as stress or
trauma, can be responsible for their clinical manifesta-
tions. This is an investigative study that probes novel
genetic mutations and polymorphisms and requires fur-
ther work with a larger population size. Nonetheless, this
research directs future studies on this poorly understood
group of disorders of bradykinin metabolism. These re-
sults demonstrate genetic variants that would affect
patients presenting with angioedema.Conclusions
Our study explored the possibility that defects in genes en-
coding proteins involved in kinin generation or catabolism
other than C1 inhibitor may be involved in angioedema.
This data suggests that a high proportion of patients with
angioedema may have various defective protein functions
leading to sustained bradykinin effects upon triggering of
its generation in AE. Functional studies addressing this
possibility would be warranted.
Our preliminary observations support the hypothesis
that the occurrence of AE attacks could be facilitated by a
variety of a variety of variants in genes encoding proteins
involved in generation and/or biodisposition of kinins
known to be mediators of this clinical syndrome. A highproportion of patients may present with genetic variants,
which needs to be verified in further studies.
In the future, patients with unusual phenotypes of AE,
including those with reduced C1-INH function, could be
investigated for gene variants associated with bradykinin
generation and degradation that are likely to contribute
to their clinical syndrome. Results of such studies could
help understand the pathophysiology of this clinically
variable syndrome. This could eventually lead to more
effective personalized therapy and prevention of attacks.
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